Abstract:Summary: A 20-year-old man with an 8-year history of progressive enlargement of his hands and feet, coarsening facial features, painful joints and thickened, oily skin was referred for investigation of acromegaly. On examination, the subject was of normal height and weight. He had markedly increased skin thickness around the forehead, eyelids and scalp with redundant skin folds. Bilateral painful knee swelling was accompanied by enlargement of the extremities, and his fingers were markedly clubbed. Routine hematological, biochemical and hormonal blood tests, including GH and IGF-1 were normal. The clinical picture suggested primary hypertrophic osteoarthropathy (PHOA) rather than acromegaly and radiological studies were supportive of this, demonstrating increased subperiosteal bone formation and increased bone density and cortical thickening. There was widespread joint disease, with narrowing of joint spaces, whereas the knees demonstrated effusions and calcification. A skull X-ray revealed calvarial hyperostosis and a normal sellar outline. Family history was negative. Genetic studies were performed on peripheral blood leukocyte DNA for mutations in the two genes associated with PHOA, 15-hydroxyprostaglandin dehydrogenase (HPGD; OMIM: 601688) and solute carrier organic anion transporter family member 2A1 (SLCO2A1; OMIM: 601460). The sequence of HPGD was normal, whereas the subject was homozygous for a novel pathological variant in SLCO2A1, c.830delT, that predicted a frameshift and early protein truncation (p.Phe277Serfs*8). PHOA, also known as pachydermoperiostosis, is a rare entity caused by abnormal prostaglandin E2 metabolism, and both HPGD and SLCO2A1 are necessary for normal prostaglandin E2 handling. High prostaglandin levels lead to bone formation and resorption and connective tissue inflammation causing arthropathy, in addition to soft tissue swelling. Learning points: The differential diagnosis of enlarged extremities, coarsened facial features, skin changes and increased sweating in suspected acromegaly is quite limited and primary hypertrophic osteoarthropathy (PHOA) is one of the few conditions that can mimic acromegaly at presentation.PHOA is not associated with abnormalities in GH and IGF-1 secretion and can be readily differentiated from acromegaly by hormonal testing.Clubbing in the setting of diffuse enlargement of joints and extremities in addition to skin changes should alert the physician to the possibility of PHOA, as clubbing is not a usual feature of acromegaly. Underlying causes of secondary hypertrophic osteoarthroapthy (e.g. bronchial neoplasia) should be considered.PHOA is a very rare condition caused by abnormalities in prostaglandin metabolism and has two known genetic causes (HPGD and SLCO2A1 mutations). SLCO2A1 gene mutations lead usually to autosomal recessive PHOA; fewer than 50 SLCO2A1 mutations have been described to date and the current case is only the second in a Hispanic patient.Treatment of primary hypertrophic osteoarthropathy is focused on the management of joint pain usually in the form of non-steroidal anti-inflammatory drug therapy.

Clinical, Biochemical, and Genetic Features of 41 Han Chinese Families with Primary Hypertrophic Osteoarthropathy, and Their Therapeutic Response to Etoricoxib: Results from a Six-Month Prospective Clinical Intervention.

Clinical and Biochemical Characteristics of 12 Chinese Primary Hypertrophic Osteoarthropathy Patients with HPGD Mutations.

Primary Hypertrophic Osteoarthropathy: Genetics, Clinical Features and Management

Characterization of Mineral and Bone Metabolism Biomarkers in a Chinese Consanguineous Twin Family with Primary Hypertrophic Osteoarthropathy.

Novel SLCO2A1compound Heterozygous Mutation Causing Primary Hypertrophic Osteoarthropathy with Bartter-like Hypokalemia in a Chinese Family

Monoallelic mutations in <i>SLCO2A1</i> cause autosomal dominant primary hypertrophic osteoarthropathy

Three Novel Mutations in the SLCO2A1 Gene in Two Chinese Families with Primary Hypertrophic Osteoarthropathy.

Targeted Exome Sequencing Identified a Novel Mutation Hotspot and a Deletion in Chinese Primary Hypertrophic Osteoarthropathy Patients.

Identification of Two Novel Mutations in the Slco2a1 Prostaglandin Transporter Gene in A Chinese Patient with Primary Hypertrophic Osteoarthropathy

Mutations in Theslco2a1gene and Primary Hypertrophic Osteoarthropathy: A Clinical and Biochemical Characterization

Clinical and basic research progress in primary hypertrophic osteoarthropathy

A novel mutation in the SLCO2A1 gene in a Chinese family with primary hypertrophic osteoarthropathy.

Two Novel Mutations in the SLCO2A1 Gene in a Chinese Patient with Primary Hypertrophic Osteoarthropathy.

Clinical analysis of primary hypertrophic osteoarthropathy (report of 5 cases)

Type Ii Primary Hypertrophic Osteoarthropathy Pedigree: A Case Report And Review Of The Literature

Progress in Diagnosis and Management of Primary Hypertrophic Osteoarthropathy

[Genetic Diagnosis for a Chinese Han Family with Primary Hypertrophic Osteoarthropathy].

Exome Sequencing Identifies Slco2a1 Mutations As A Cause of Primary Hypertrophic Osteoarthropathy

Primary Hypertrophic Osteoarthropathy with SLCO2A1 Mutation in a Chinese Patient Successfully Treated with Etoricoxib

Primary hypertrophic osteoarthropathy due to a novel SLCO2A1 mutation masquerading as acromegaly

Novel SLCO2A1 Mutations Cause Gender-Differentiated Pachydermoperiostosis